

ASX Release
ASX Code: MEM

2 April 2026

Memphasys to Host Investor Webinar Highlighting Global Commercial Expansion and Growing Recurring Revenues

Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) is pleased to advise that it will host an investor webinar on Wednesday, 8 April 2026, during which Director Marjan Mikel will present an update on the Company’s commercial progress and outlook.

The webinar will include a presentation of the Company’s latest investor deck, providing an overview of recent developments across regulatory approvals, market entry, and early-stage revenue generation, as well as the strategy to scale commercialisation across multiple jurisdictions.

Webinar Details

- **Date:** Wednesday, 8 April 2026
- **Time:** 9:00am AWST / 11am AEST
- **Presenter:** Marjan Mikel, Director
- **Format:** Presentation followed by live Q&A

Participants will have the opportunity to submit questions during the session, which will be addressed following the presentation, time permitting.

Focus of Presentation

The presentation will outline:

- Progress in commercial rollout of the Felix™ System across key markets
- Recent regulatory milestones supporting broader market access
- Early revenue traction and clinic-level adoption
- Strategy to scale recurring cartridge revenue through installed systems
- Outlook for continued expansion into new geographies

Registration

Investors and stakeholders are invited to register for the webinar via the following link:

https://us02web.zoom.us/webinar/register/WN_qaiHOMp-SPezbr_bZCG2CQ

This announcement has been authorised for release by the Board of Memphasys Limited.

ENDS

For further information, please contact:

David Tasker
Managing Director
Chapter One Advisors
Tel: +61 433 112 936
E: dtasker@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.

By combining electrophoresis and size-exclusion membranes, Felix™ delivers a fast, gentle and standardised sperm selection process that enhances sperm quality and reduces laboratory time. The system replaces traditional centrifugation, which can cause cellular stress and DNA damage, offering clinicians a superior, repeatable alternative.

Memphasys' commercial strategy focuses on building contracted sales through direct and distribution-led channels, scaling production to improve margins, and establishing Felix™ as a new global standard in sperm preparation for ART procedures.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.